Copyright
©The Author(s) 2020.
World J Gastroenterol. Feb 28, 2020; 26(8): 839-849
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.839
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.839
Table 1 Clinical characteristics of the entire patient cohort
Characteristics | Values |
Age in yr | 59.8 ± 8.4 |
Sex | |
Male | 1288 (83.4%) |
Female | 257 (16.6%) |
BMI in kg/m2 | |
< 18.5 | 212 (13.8%) |
18.5-24.9 | 1144 (74.0%) |
25.0-29.9 | 172 (11.1%) |
≥ 30.0 | 17 (1.1%) |
Weight change | |
Weight stable | 986 (63.8%) |
Weight loss | 559 (36.2%) |
Tumor location | |
Upper | 133 (8.6%) |
Middle | 938 (60.7%) |
Lower | 386 (25.0%) |
Cardia | 88 (5.7%) |
Histological grade | |
Well differentiated | 57 (3.7%) |
Moderately differentiated | 625 (40.5%) |
Poorly differentiated | 789 (51.1%) |
Others | 74 (4.8%) |
T stage | |
Tis | 38 (2.5%) |
T1 | 187 (12.1%) |
T2 | 292 (18.9%) |
T3 | 731 (47.3%) |
T4a | 297 (19.2%) |
N stage | |
N0 | 891 (57.7%) |
N1 | 374 (24.2%) |
N2 | 217 (14.0%) |
N3 | 63 (4.1%) |
Surgical approach | |
Sweet | 1256 (81.3%) |
Ivor-Lewis | 146 (9.4%) |
McKeown | 143 (9.3%) |
Lymphovascular invasion | |
Yes | 75 (4.9%) |
No | 1470 (95.1%) |
Adjuvant therapy | |
Yes | 575 (37.2%) |
No | 970 (62.8%) |
Table 2 Optimal cut-off point for body mass index
Deciles of BMI | χ2 | HR | 95%CI | P value |
1 vs 2-10 | 14.5 | 1.5 | 1.2-1.8 | 0.000 |
1-2 vs 3-10 | 15.9 | 1.4 | 1.2-1.6 | 0.000 |
1-3 vs 4-10 | 24.5 | 1.4 | 1.2-1.6 | 0.000 |
1-4 vs 5-10 | 21.6 | 1.4 | 1.2-10.6 | 0.000 |
1-5 vs 6-10 | 18.6 | 1.3 | 1.2-1.5 | 0.000 |
1-6 vs 7-10 | 15.1 | 1.3 | 1.1-1.5 | 0.000 |
1-7 vs 8-10 | 14.1 | 1.3 | 1.1-1.5 | 0.000 |
1-8 vs 9-10 | 7.5 | 1.3 | 1.1-1.5 | 0.006 |
1-9 vs 10 | 6.2 | 1.3 | 1.1-1.7 | 0.013 |
Table 3 Optimal cut-off point for preoperative weight loss
Deciles of PWL | χ2 | HR | 95%CI | P |
ws vs all | 19.2 | 1.3 | 1.2-1.5 | 0.000 |
ws + 10 vs 1-9 | 17.9 | 1.3 | 1.2-1.5 | 0.000 |
ws + 10-9 vs 1-8 | 20.3 | 1.4 | 1.2-1.6 | 0.000 |
ws + 10-8 vs 1-7 | 23.9 | 1.4 | 1.2-1.6 | 0.000 |
ws + 10-7 vs 1-6 | 26.1 | 1.5 | 1.3-1.7 | 0.000 |
ws + 10-6 vs 1-5 | 24.8 | 1.5 | 1.3-1.7 | 0.000 |
ws + 10-5 vs 1-4 | 34.4 | 1.6 | 1.4-1.9 | 0.000 |
ws + 10-4 vs 1-3 | 48.4 | 1.8 | 1.5-2.2 | 0.000 |
ws + 10-3 vs 1-2 | 35.5 | 1.9 | 1.5-2.3 | 0.006 |
ws + 10-2 vs 1 | 14.8 | 1.8 | 1.3-2.4 | 0.013 |
Table 4 Combined analysis of preoperative weight loss and body mass index (sample size)
BMI in kg/m2 | ||
PWL, % | ≥ 20 | < 20 |
0-8.8 | 1033 | 351 |
≥ 8.8 | 70 | 99 |
Table 5 Combined analysis of preoperative weight loss and body mass index (median overall survival, mo)
BMI in kg/m2 | ||
PWL, % | ≥ 20 | < 20 |
0-8.8 | 45.3 | 29.5 |
≥ 8.8 | 23.5 | 17.4 |
Table 6 Combined analysis of preoperative weight loss and body mass index (unadjusted estimated hazard ratios)
BMI in kg/m2 | ||
PWL, % | ≥ 20 | < 20 |
0-8.8 | 1 | 1.289 (1.105-1.505) |
≥ 8.8 | 1.913 (1.453-2.519) | 2.02 (1.592-2.567) |
Table 7 Predictors of overall survival in univariable and multivariable analyses
Variables | Univariate analyses | Multivariate analyses | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | 1.16 | 1.00-1.33 | 0.038 | 1.11 | 0.97-1.27 | 0.136 |
Sex, M/F | 1.32 | 1.10-1.58 | 0.002 | 1.19 | 0.99-1.43 | 0.066 |
TNM stage | 2.56 | 2.24-2.92 | 0.000 | 2.52 | 2.20-2.89 | 0.000 |
Adjuvant therapy | 0.86 | 0.75-0.98 | 0.027 | 0.75 | 0.66-0.86 | 0.000 |
Group 1 | 1 | |||||
Group 2 | 1.29 | 1.11-1.51 | 0.001 | 1.19 | 1.02-1.39 | 0.030 |
Group 3 | 1.96 | 1.62-2.37 | 0.000 | 1.63 | 1.35-1.98 | 0.000 |
- Citation: Zhang HL, Yang YS, Duan JN, Shang QX, He SL, Gu YM, Hu WP, Wang WP, Hu Y, Wang Y, Yuan Y, Chen LQ. Prognostic value of preoperative weight loss-adjusted body mass index on survival after esophagectomy for esophageal squamous cell carcinoma. World J Gastroenterol 2020; 26(8): 839-849
- URL: https://www.wjgnet.com/1007-9327/full/v26/i8/839.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i8.839